News >

FDA Approves Nivolumab for Head and Neck Cancer

Jason M. Broderick @jasoncology
Published: Thursday, Nov 10, 2016

The FDA has approved nivolumab (Opdivo) for patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN) following progression on platinum-based therapy.

Since its initial approval for patients with melanoma in 2014, nivolumab has received numerous additional indications. The agent is approved for patients with non–small cell lung cancer, renal cell carcinoma, and classical Hodgkin lymphoma, as well as for patients with melanoma as a single-agent and with the CTLA-4 inhibitor ipilimumab (Yervoy).
Ferris RL, Blumenschein GR, Fayette J, et al. Further evaluations of nivolumab (nivo) versus investigator’s choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141. J Clin Oncol. 2016;34 (suppl; abstr 6009).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
Publication Bottom Border
Border Publication
x